Optimal dynamic control approach in a multi-objective therapeutic scenario: Application to drug delivery in the treatment of prostate cancer

por Irurzun-Arana, Itziar, Janda, Alvaro, Ardanza-Trevijano, Sergio, Trocóniz, Iñaki F.
Publicado 2018

Predicting circulating biomarker response and its impact on the survival of advanced melanoma patients treated with adjuvant therapy

por Irurzun-Arana, Itziar, Asín-Prieto, Eduardo, Martín-Algarra, Salvador, Trocóniz, Iñaki F.
Publicado 2020

Beyond Deterministic Models in Drug Discovery and Development

por Irurzun-Arana, Itziar, Rackauckas, Christopher, McDonald, Thomas O., Trocóniz, Iñaki F.
Publicado 2020

Investigational treatments for COVID-19 may increase ventricular arrhythmia risk through drug interactions

por Varshneya, Meera, Irurzun-Arana, Itziar, Campana, Chiara, Dariolli, Rafael, Gutierrez, Amy, Pullinger, Taylor K., Sobie, Eric A.
Publicado 2020

Investigational Treatments for COVID‐19 may Increase Ventricular Arrhythmia Risk Through Drug Interactions

por Varshneya, Meera, Irurzun-Arana, Itziar, Campana, Chiara, Dariolli, Rafael, Gutierrez, Amy, Pullinger, Taylor K., Sobie, Eric A.
Publicado 2021

Investigational Treatments for COVID-19 May Increase Ventricular Arrhythmia Risk through Drug Interactions

por Varshneya, Meera, Irurzun-Arana, Itziar, Campana, Chiara, Dariolli, Rafael, Gutierrez, Amy, Pullinger, Taylor K., Sobie, Eric A.
Publicado 2021

A systems pharmacology model for inflammatory bowel disease

por Balbas-Martinez, Violeta, Ruiz-Cerdá, Leire, Irurzun-Arana, Itziar, González-García, Ignacio, Vermeulen, An, Gómez-Mantilla, José David, Trocóniz, Iñaki F.
Publicado 2018

Semimechanistic models to relate noxious stimulation, movement, and pupillary dilation responses in the presence of opioids

por Marco‐Ariño, Nicolás, Vide, Sergio, Agustí, Mercè, Chen, Andrew, Jaramillo, Sebastián, Irurzun‐Arana, Itziar, Pacheco, Adrià, Gonzalez, Carmen, Jensen, Erik W., Capsi‐Morales, Patricia, Valencia, José F., Troconiz, Iñaki F., Gambus, Pedro L., Larson, Merlin D.
Publicado 2021

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer

por Kwon, Minsuk, Kim, Gahyun, Kim, Ryul, Kim, Kyu-Tae, Kim, Seung Tae, Smith, Simon, Mortimer, Peter G S, Hong, Jung Yong, Loembé, Arsene-Bienvenu, Irurzun-Arana, Itziar, Koulai, Loumpiana, Kim, Kyoung-Mee, Kang, Won Ki, Dean, Emma, Park, Woong-Yang, Lee, Jeeyun
Publicado 2022

Phase I Study of Ceralasertib (AZD6738), a Novel DNA Damage Repair Agent, in Combination with Weekly Paclitaxel in Refractory Cancer

por Kim, Seung Tae, Smith, Simon A., Mortimer, Peter, Loembé, Arsene-Bienvenu, Cho, Heejin, Kim, Kyoung-Mee, Smith, Claire, Willis, Sophie, Irurzun-Arana, Itziar, Berges, Alienor, Hong, Jung Yong, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kozarewa, Iwanka, Pierce, Andrew J., Dean, Emma, Lee, Jeeyun
Publicado 2021

Ceralasertib (AZD6738), an Oral ATR Kinase Inhibitor, in Combination with Carboplatin in Patients with Advanced Solid Tumors: A Phase I Study

por Yap, Timothy A., Krebs, Matthew G., Postel-Vinay, Sophie, El-Khouiery, Anthony, Soria, Jean-Charles, Lopez, Juanita, Berges, Alienor, Cheung, S.Y. Amy, Irurzun-Arana, Itziar, Goldwin, Andrew, Felicetti, Brunella, Jones, Gemma N., Lau, Alan, Frewer, Paul, Pierce, Andrew J., Clack, Glen, Stephens, Christine, Smith, Simon A., Dean, Emma, Hollingsworth, Simon J.
Publicado 2021